ZGNX Brean initiation report (partial) Future Looks Brighter for Zogenix, Initiate with BUY and $2.50 TP Investment Summary We are initiating coverage of Z, Inc. with a BUY rating and a $2.50 TP. Zogenix has commercialized a controversial product, Z ER, and we believe the market under-appreciates the medical value this product brings to patients and pain-treating specialists. Despite the heated debate and intense negative coverage from the media, we are impressed that the product is performing well during early launch days.
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.